Literature DB >> 31865445

Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.

Enrique Esteve-Valverde1, Alfonso Tapiz-Reula1, Domingo Ruiz1,2, Jaume Alijotas-Reig3,4.   

Abstract

Porphyrias, particularly acute intermittent porphyria (AIP), are rare disorders which could be associated with systemic lupus erythematosus (SLE). Although the association with AIP has been known since 1952, only 11 cases have been published to date. It is widely known that precipitating causes such as infections, hormonal changes, sunlight exposure, stress and drugs could provoke an AIP crisis. Hydroxychloroquine (HCQ) is usually used in lupus patients, but rarely appears to trigger AIP crises even in SLE patients. The case of a 51-year-old man in whom AIP onset was probably due to hydroxychloroquine use during SLE management is presented. SLE onset was accompanied by fever, pleural, lung and joint involvement with a characteristic SLE autoantibody panel. Although prednisone was given, the joint symptoms did not subside. HCQ was then started; however, some days later the patient suffered anxiety, vomiting and severe abdominal pain refractory to pain-relief drugs and liver function had worsened. No cutaneous lesions were observed. The patient suffered similar episodes accompanied by paralytic ileus and dark-coloured urine, the sediment of which showed no abnormalities. In addition, no myoglobinuria was found. This finding raised the suspicion of AIP and urine tests revealed elevated values of delta-aminolevulinic acid and porphobilinogen. Hydroxychloroquine was preventively suspended and the patient improved notably within a few days. In the following months, the patient suffered no relapse and the prednisone dose could be lowered. Finally, a review of the literature on this topic highlighted the exceptional nature of an API/ SLE association particularly in men. Interestingly, porphyria may present first followed by SLE, or vice versa. The latency period between drug administration and disease onset varies from days to 2 years. Both chloroquine and HCQ may induce PAI in SLE patients. Clinicians should be alerted to a possible association with AIP when a patient with SLE recently put on HCQ presents acute onset of abdominal and/or neurological symptoms and dark urine. Appropriate tests and prompt HCQ cessation are mandatory.

Entities:  

Keywords:  Acute intermittent porphyria; Antimalarials; Hydroxychloroquine; Porphyria crisis; Systemic lupus erythematosus; Treatment

Mesh:

Substances:

Year:  2019        PMID: 31865445     DOI: 10.1007/s00296-019-04500-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  39 in total

1.  [Exacerbated chronic lupus erythematosus and acute porphyria].

Authors:  H N PASSARON; J H LLOVERAS; E VAZQUEZ
Journal:  Arch Argent Dermatol       Date:  1962-09

2.  [Colic caused by porphyrin; symptomatology of the acute erythematodes].

Authors:  S WOLFRAM
Journal:  Hautarzt       Date:  1952-07       Impact factor: 0.751

Review 3.  [Systemic lupus erythematosus and intermittent acute porphyria. Association or coincidence?].

Authors:  F Vittori; J L Desaegher
Journal:  Sem Hop       Date:  1977 Jul 10-20

Review 4.  Hydroxychloroquine: a multifaceted treatment in lupus.

Authors:  Nathalie Costedoat-Chalumeau; Bertrand Dunogué; Nathalie Morel; Véronique Le Guern; Gaëlle Guettrot-Imbert
Journal:  Presse Med       Date:  2014-05-19       Impact factor: 1.228

5.  [Systemic lupus erythematosus and acute intermittent porphyria].

Authors:  R Quilichini; A Guerder
Journal:  Nouv Presse Med       Date:  1973-04

Review 6.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

Review 7.  The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.

Authors:  D J Wallace
Journal:  Lupus       Date:  1996-06       Impact factor: 2.911

8.  Hypertension and renal disease in patients with acute intermittent porphyria.

Authors:  C Andersson; F Lithner
Journal:  J Intern Med       Date:  1994-08       Impact factor: 8.989

Review 9.  Acute Hepatic Porphyrias: Review and Recent Progress.

Authors:  Bruce Wang; Sean Rudnick; Brent Cengia; Herbert L Bonkovsky
Journal:  Hepatol Commun       Date:  2018-12-20

Review 10.  An update of clinical management of acute intermittent porphyria.

Authors:  Elena Pischik; Raili Kauppinen
Journal:  Appl Clin Genet       Date:  2015-09-01
View more
  1 in total

1.  Systemic Lupus Erythematosus and Hereditary Coproporphyria: Two Different Entities Diagnosed by WES in the Same Patient.

Authors:  Anlei Liu; Lingli Zhou; Huadong Zhu; Yi Li; Jing Yang
Journal:  Biomed Res Int       Date:  2022-05-28       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.